Clinical and molecular stratification of disease risk in medulloblastoma

Abstract

The accurate assessment of disease risk among children with medulloblastoma remains a major challenge to the field of paediatric neuro-oncology. In the current study we investigated the capacity of molecular abnormalities to increase the accuracy of disease risk stratification above that afforded by clinical staging alone. 41 primary medulloblastoma tumour samples were analysed for ErbB2 receptor expression using immunohistochemistry, and for aberrations of chromosome 17 and amplification of the MYC oncogene using fluorescence in situ hybridisation. The ErbB2 receptor and deletion of 17p were detected in 80% and 49% of tumours, respectively. 17p loss occurred either in isolation (20%), or in association with gain of 17q (29%), compatible with an isochromosome of 17q. Amplification of MYC was detected in only 2 tumours. Significant prognostic factors included, 'metastatic disease' (P = 0.0006), 'sub-total tumour resection' (P = 0.007), 'high ErbB2 receptor expression' (P = 0.003) and 'isolated 17p loss' (P = 0.003). Combined analysis of clinical and molecular factors enabled greater resolution of disease risk than clinical factors alone, identifying a sub-population of patients with particularly favourable disease outcome. These data support the hypothesis that a combination of clinical and molecular factors may afford a more reliable means of assigning disease risk in patients with medulloblastoma, thereby providing a more accurate basis for targeting therapy in children with this disease.

References 23

1. 1.

   Badiali M., Pession A., Basso G., Andreini L., Rigobello L., Galassi E., Giangaspero F. N-myc and c-myc oncogenes amplification in medulloblastomas. Evidence of particularly aggressive behavior of a tumor with c-myc amplification. Tumori. 1991;77(2):118-121.

   Not in our library10.1177/030089169107700205

2. 2.

   Bailey C. C., Gnekow A., Wellek S., Jones M., Round C., Brown J., Phillips A., Neidhardt M. K. Prospective randomised trial of chemotherapy given before radiotherapy in childhood medulloblastoma. International Society of Paediatric Oncology (SIOP) and the (German) Society of Paediatric Oncology (GPO): SIOP II. Med Pediatr Oncol. 1995;25(3):166-178.

   Not in our library10.1002/mpo.2950250303

3. 3.

   Batra S. K., McLendon R. E., Koo J. S., Castelino-Prabhu S., Fuchs H. E., Krischer J. P., Friedman H. S., Bigner D. D., Bigner S. H. Prognostic implications of chromosome 17p deletions in human medulloblastomas. J Neurooncol. 1995;24(1):39-45.

   Not in our library10.1007/bf01052657

4. 4.

   Biegel J. A., Janss A. J., Raffel C., Sutton L., Rorke L. B., Harper J. M., Phillips P. C. Prognostic significance of chromosome 17p deletions in childhood primitive neuroectodermal tumors (medulloblastomas) of the central nervous system. Clin Cancer Res. 1997;3(3):473-478.

   Not in our library

5. 5.

   Cobleigh M. A., Vogel C. L., Tripathy D., Robert N. J., Scholl S., Fehrenbacher L., Wolter J. M., Paton V., Shak S., Lieberman G. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 1999;17(9):2639-2648.

   Not in our library10.1200/jco.1999.17.9.2639

6. 6.

   Cogen P. H. Prognostic significance of molecular genetic markers in childhood brain tumors. Pediatr Neurosurg. 1991;17(5):245-250.

   Not in our library10.1159/000120605

7. 7.

   Emadian S. M., McDonald J. D., Gerken S. C., Fults D. Correlation of chromosome 17p loss with clinical outcome in medulloblastoma. Clin Cancer Res. 1996;2(9):1559-1564.

   Not in our library

8. 8.

   Gilbertson R. J., Clifford S. C., MacMeekin W., Meekin W., Wright C., Perry R. H., Kelly P., Pearson A. D., Lunec J. Expression of the ErbB-neuregulin signaling network during human cerebellar development: implications for the biology of medulloblastoma. Cancer Res. 1998;58(17):3932-3941.

   Not in our library

9. 9.

   Gilbertson R. J., Jaros E., Perry R. H., Kelly P. J., Lunec J., Pearson A. D. Mitotic percentage index: a new prognostic factor for childhood medulloblastoma. Eur J Cancer. 1997;33(4):609-615.

   Not in our library10.1016/s0959-8049(96)00516-3

10. 10.

    Gilbertson R. J., Perry R. H., Kelly P. J., Pearson A. D., Lunec J. Prognostic significance of HER2 and HER4 coexpression in childhood medulloblastoma. Cancer Res. 1997;57(15):3272-3280.

    Not in our library

11. 11.

    Herms J. W., Behnke J., Bergmann M., Christen H. J., Kolb R., Wilkening M., Markakis E., Hanefeld F., Kretzschmar H. A. Potential prognostic value of C-erbB-2 expression in medulloblastomas in very young children. J Pediatr Hematol Oncol. 1997;19(6):510-515.

    Not in our library10.1097/00043426-199711000-00004

12. 12.

    Herms J., Neidt I., Lüscher B., Sommer A., Schürmann P., Schröder T., Bergmann M., Wilken B., Probst-Cousin S., Hernáiz-Driever P. C-MYC expression in medulloblastoma and its prognostic value. Int J Cancer. 2000;89(5):395-402.

    Not in our library

13. 13.

    Kortmann R. D., Kühl J., Timmermann B., Mittler U., Urban C., Budach V., Richter E., Willich N., Flentje M., Berthold F. Postoperative neoadjuvant chemotherapy before radiotherapy as compared to immediate radiotherapy followed by maintenance chemotherapy in the treatment of medulloblastoma in childhood: results of the German prospective randomized trial HIT '91. Int J Radiat Oncol Biol Phys. 2000;46(2):269-279.

    Not in our library10.1016/s0360-3016(99)00369-7

14. 14.

    Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966;50(3):163-170.

    Not in our library

15. 15.

    Nicholson J., Wickramasinghe C., Ross F., Crolla J., Ellison D. Imbalances of chromosome 17 in medulloblastomas determined by comparative genomic hybridisation and fluorescence in situ hybridisation. Mol Pathol. 2000;53(6):313-319.

    Not in our library10.1136/mp.53.6.313

16. 16.

    Olayioye M. A., Neve R. M., Lane H. A., Hynes N. E. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J. 2000;19(13):3159-3167.

    Not in our library10.1093/emboj/19.13.3159

17. 17.

    Packer R. J., Goldwein J., Nicholson H. S., Vezina L. G., Allen J. C., Ris M. D., Muraszko K., Rorke L. B., Wara W. M., Cohen B. H. Treatment of children with medulloblastomas with reduced-dose craniospinal radiation therapy and adjuvant chemotherapy: A Children's Cancer Group Study. J Clin Oncol. 1999;17(7):2127-2136.

    Not in our library10.1200/jco.1999.17.7.2127

18. 18.
    Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples · 1977

    No notice
19. 19.

    Scheurlen W. G., Schwabe G. C., Joos S., Mollenhauer J., Sörensen N., Kühl J. Molecular analysis of childhood primitive neuroectodermal tumors defines markers associated with poor outcome. J Clin Oncol. 1998;16(7):2478-2485.

    Not in our library10.1200/jco.1998.16.7.2478

20. 20.

    Scheurlen W. G., Seranski P., Mincheva A., Kühl J., Sörensen N., Krauss J., Lichter P., Poustka A., Wilgenbus K. K. High-resolution deletion mapping of chromosome arm 17p in childhood primitive neuroectodermal tumors reveals a common chromosomal disruption within the Smith-Magenis region, an unstable region in chromosome band 17p11.2. Genes Chromosomes Cancer. 1997;18(1):50-58.

    Not in our library10.1002/(sici)1098-2264(199701)18:1<50::aid-gcc6>3.0.co;2-0

21. 21.

    Schwartz C. L. Long-term survivors of childhood cancer: the late effects of therapy. Oncologist. 1999;4(1):45-54.

    Not in our library

22. 22.

    Thomas P. R., Deutsch M., Kepner J. L., Boyett J. M., Krischer J., Aronin P., Albright L., Allen J. C., Packer R. J., Linggood R. Low-stage medulloblastoma: final analysis of trial comparing standard-dose with reduced-dose neuraxis irradiation. J Clin Oncol. 2000;18(16):3004-3011.

    Not in our library10.1200/jco.2000.18.16.3004

23. 23.

    Zeltzer P. M., Boyett J. M., Finlay J. L., Albright A. L., Rorke L. B., Milstein J. M., Allen J. C., Stevens K. R., Stanley P., Li H. Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children's Cancer Group 921 randomized phase III study. J Clin Oncol. 1999;17(3):832-845.

    Not in our library10.1200/jco.1999.17.3.832

Cited by papers we hold 2

• Inactivation of Ezh2 Upregulates Gfi1 and Drives Aggressive Myc-Driven Group 3 Medulloblastoma · 2017
  Not checked
• Integrated Genomics Identifies Five Medulloblastoma Subtypes with Distinct Genetic Profiles, Pathway Signatures and Clinicopathological Features · 2008
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.